

117TH CONGRESS  
2D SESSION

# S. 3809

To require the Comptroller General of the United States to conduct a study relating to COVID–19 immunity resulting from a prior infection, vaccination, or both, and the COVID–19 pandemic.

---

## IN THE SENATE OF THE UNITED STATES

MARCH 10 (legislative day, MARCH 7), 2022

Mr. BRAUN (for himself and Mr. MARSHALL) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

---

## A BILL

To require the Comptroller General of the United States to conduct a study relating to COVID–19 immunity resulting from a prior infection, vaccination, or both, and the COVID–19 pandemic.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Apply the Science  
5       Act”.

1 **SEC. 2. GAO STUDY ON NATURAL IMMUNITY IN RELATION**  
2 **TO THE COVID-19 PANDEMIC.**

3 (a) STUDY.—Not later than 180 days after the date  
4 of enactment of this Act, the Comptroller General of the  
5 United States shall conduct a study to determine the fol-  
6 lowing:

7 (1) What is the current scientific understanding  
8 of the duration and effectiveness of COVID-19 im-  
9 munity resulting from a prior infection, vaccination,  
10 or both, including any differences across population  
11 groups.

12 (2) To what extent does the Centers for Disease  
13 Control and Prevention make available, to key stake-  
14 holders, the body of work it has assessed to inform  
15 its policy decisions related to COVID-19 infection-  
16 acquired and vaccine-induced immunity.

17 (3) To what extent do select foreign countries  
18 take into account the scientific evidence pertaining  
19 to COVID-19 infection-acquired immunity when cre-  
20 ating public health regulations or guidance.

21 (4) To what extent can diagnostic tests that  
22 measure the immune response be better utilized in  
23 a comprehensive COVID-19 response, including in  
24 high-risk population groups, and barriers to current  
25 use of these diagnostic tests.

1       (b) REPORT.—Not later than 18 months after the  
2 date of enactment of this Act, the Comptroller General  
3 of the United States shall submit to the appropriate com-  
4 mittees of Congress a report on the determinations made  
5 pursuant to subsection (a).

○